logo
Katie Thurston Gives Candid Look at Being in ‘Medically Induced Menopause' at 34 Amid Cancer Battle

Katie Thurston Gives Candid Look at Being in ‘Medically Induced Menopause' at 34 Amid Cancer Battle

Yahoo20-07-2025
Former Bachelorette Katie Thurston is opening up about a rarely discussed side effect of her stage IV breast cancer battle.
'What it's like to have hot flashes due to medically induced menopause,' Thurston, 34, wrote via her Instagram Stories on Sunday, July 20, sharing a screenshot of her Apple Health chart.
Per a screenshot, Thurston spent eight hours and 54 minutes in bed, but she was only asleep for just over six hours.
'I have the option to add a prescription to the routine of meds I'm on, but tbh I'm just simply scared,' Thurston wrote in her caption. 'Every added pill comes with a new risk for side effects. But, I might be reaching my breaking point when it comes to quality of life.'
Katie Thurston Details How Intimacy With Husband Jeff Arcuri Has Changed Since Breast Cancer Battle
She continued, 'I'm always tired and uncomfortable.'
Thurston was diagnosed with breast cancer in February, later discovering that the malignant tissue had spread to her liver, which elevated her diagnosis to stage IV. In order to adequately treat her specific type of cancer, doctors had to put her body into early menopause.
'Slept like s*** because I'm now in medically induced menopause, which means I get hot flashes,' she said in a social media video posted in May. 'Tonight I have to be social so I figured I would ease into that by being social with you guys during the day. In the meantime, show you kind of what a normal day looks like for me.'
She added at the time, 'My lips have been chapped for what feels like two weeks straight. And so it's this game of, like, catch-up and trying to just make sure I get enough water. Which I was already bad at before medication and now it's like a true task every day to force myself to consume water. So, good morning!'
Before Thurston went into menopause, she did a round of in vitro fertilization and froze embryos.
'I'm basically putting my ovaries into a temporary menopausal state (I like to say hibernation) to protect them from chemo,' Thurston said in a March Instagram update. 'It will also reduce estrogen production, which is particularly important in hormonereceptor-ER+/PR+ breast cancer as estrogen can fuel cancer growth.'
A Timeline of Former Bachelorette Katie Thurston's Breast Cancer Battle: From Diagnosis to Treatment
Thurston and her husband, Jeff Arcuri, also plan to use a surrogate to carry any future children down the line. Us Weekly exclusively confirmed earlier in March that the pair tied the knot.
'We were wanting to plan a wedding and there's a lot of emotions that come in with chemo and the impact and the health and we don't know what the next year looks like,' Thurston told Us. 'And one night he said, 'I want to show you that I still love you and that I'm here to stay. I'll get married to you tomorrow.' We flew our parents in from Michigan and Washington State. We got our marriage license and a friend is just gonna marry us.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

time18 minutes ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

Yahoo

time18 minutes ago

  • Yahoo

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

time18 minutes ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store